An update on safety and supply issues relating to blood and therapeutic products used by people with bleeding disorders. This will include discussion of product recalls the past two years, the January 2020 NBDF/HFA Safety Summit convened by the…
When you have an ultra-rare bleeding disorder, it can be difficult to find the kind of specialized support you need. You need to talk to experts who understand the nuances of your disorder, and a community that knows what you’re going…
When you live with hemophilia with an inhibitor, you and your family have questions and concerns that deserve special attention. NHF’s 2021 Virtual Inhibitor Education Series will provide just that – quality education…
Octapharma recently announced the final results from the NuProtect study, which evaluated the immunogenicity of Nuwiq® in previously untreated patients (PUPs) with severe hemophilia A.Nuwiq® is a recombinant factor VIII therapy, is indicated for on-…
Spark Therapeutics announced preliminary data from part one of their ongoing phase 1/2 open-label, non-randomized, dose-finding study of SPK-8016, the company’s investigational gene therapy for hemophilia A. Part one is designed to evaluate the…
Joint statement from the European Hemophilia Consortium, the World Federation of Hemophilia, and the National Hemophilia Foundation
Fitusiran update following EAHAD 2021 Congress
Fitusiran is an RNA drug that can prevent…